Tagged parkinson-s-disease
Press Release
Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms Read More
Press Release
Consumer Safety Watch Reports That the Senate Has Voted to Pass the Camp Lejeune Justice Act and the Honoring Our PACT Act
According to Chris Powell of Consumer Safety Watch, the vote was 84-14 Thursday to pass the Honoring Our PACT Act, H.R. 3967 (117), requiring broadened Department of Veterans Affairs coverage for toxic exposure related to burn pits and contaminated water Read More
Press Release
Parkinson's Foundation Appoints Utah Tech CEO Cory Pinegar as President and Board Member of Newly Formed Rocky Mountain Chapter Board of Advisors
The appointment is set to increase area resources and further elevate awareness of the disease, which has impacted the Pinegar family Read More
Press Release
GB Sciences Files Provisional Patent Application for the Treatment of Chronic Inflammation Utilizing Its Novel Cannabinoid Containing Complex Mixtures (CCCM)
This marks the 11th U.S. provisional patent application filed by GBS covering the use of CCCM™ for unique medical disorders, creating an IP portfolio that contains formulas for up to 50 potential therapeutic indications. Read More
Press Release
GB Sciences Announces Issuance of US Patent for Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease
This is the first time a Cannabinoid-Containing Complex Mixture (CCCM™) has been awarded a U.S. patent, which thereby validates GB Sciences' drug discovery platform and strengthens its intellectual property patent portfolio Read More
Press Release
GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada
GBS Global Biopharma, Inc., the Canadian holding of GB Sciences, signed an Amendment to their Agreement with the National Research Council of Canada (NRC) to include valuable testing of Mechanism of Action for its Parkinson's Disease (PD) Formulations to strengthen their Investigational New Drug (IND) Application to the US FDA in preparation for human trials addressing a $52 billion market in the US alone. Read More
Press Release
Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation
Study aims to identify novel blood-based inflammatory markers that can be used to both identify and stratify Parkinson's disease patients Read More
Press Release
To Resolve the Mystery of the Body Movement May Treat Parkinson's Disease
Recently, in two research papers published in the journal Cell and Neuron, scientists at the Gladstone institutes found special neural circuits controlling walking through the study. At the same time, they also found that the circuit input was interrupted in Parkinson's disease patients. Read More
Press Release
Parkinson's Patients in India Need More Resources, World Parkinson's Program Emphasizes
A Canadian based non-profit organization, World Parkinson's Program, held a seminar in Delhi, India to lecture about Parkinson's disease. The lectures included multiple topics, and included a question and answer period. Those who attended included physicians, neurologists and other healthcare professionals from India. Read More
Press Release
